Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,306 total articles
Invivyd is a small-cap antibody specialist with a commercial COVID product (PEMGARDA) producing real revenue and a Phase 3 readout for vaccine-alternative VYD2311 expected mid-2026. Market cap is roughly $406M while the company reports accelerating quarterly product sales and has recently bolstered the balance sheet. This trade idea outlines an act…
Astera Labs has been a high-flying supplier to the AI data-center buildout, but today's price action and the capitalized expectations do not yet square with a pullback in sentiment. With a market cap near $20.4B, P/E north of 100, and EV/Sales approaching 25x, the setup looks vulnerable. We outline a swing short with clear entry, stop and target le…
Microsoft trades at a multitrillion-dollar valuation that assumes continued high-margin, high-growth outcomes while price-to-free-cash-flow and price-to-sales imply little room for execution slip. With heavy AI and cloud spending increasingly front-loaded and fundamentals showing stretched multiples, a mid-term short targets mean reversion toward t…
Goldman Sachs (GS) is trading at roughly $811.57 and offers a compelling risk/reward for a mid-term swing: attractive P/E and P/B relative to its history, robust free cash flow, and a business that benefits from market volatility. This idea lays out an entry at $811.57, a stop at $760.00, and a target of $900.00 with a preferred horizon of mid term…
Rocket Lab (RKLB) is trading at $69.75 after a pullback from its 52-week high. The company’s fast launch cadence, record 2025 revenue of $602M and a $1.85B backlog set the stage for high growth as Neutron development progresses toward a Q4 2026 debut. This trade idea proposes a speculative long: entry $69.75, stop $62.00, target $95.00 for a mid-te…
Micron just reported a blowout fiscal Q2 with revenue of $23.86B and net income near $13.8B as AI infrastructure drove HBM and data-center demand. The market is debating whether Micron's $25B+ fiscal 2026 capex derails margins or cements a multi-year lead. This trade idea takes a long stance: buy on weakness with defined risk and a 180-trading-day …
Uber is no longer just a ride-hail marketplace. With recent deals that include a $1.25B commitment to Rivian and deeper ties to Nvidia, Uber is positioning its demand network and capital-light deployment model to capture growth from autonomous vehicles. Fundamentals support a reasonably valued growth story: market cap roughly $153B, P/E ~16, positi…
Nvidia remains the essential supplier to the AI buildout. Fundamentals and cash generation support a constructive mid-term trade: enter around $176, stop $165, target $230 over the next 45 trading days. Valuation is rich but survivable given $96.7B in free cash flow and near-monopoly positions in datacenter GPUs and networking.
Satellogic offers a high-upside long trade backed by accelerating product capability (30 cm NextGen), expanding sovereign and distribution contracts, and improving technicals. Valuation is rich versus current revenue, but recent contract wins, a $90M capital raise and in-orbit asset monetization provide a path to justify a re-rate. Long trade plan …
Paramount Skydance (PSKY) is trading at roughly $9 with a market cap near $10.0B after a bruising bidding war and a headline-grabbing $111B deal for Warner Bros. Discovery. The balance sheet and deal mechanics create large execution risk; still, low price-to-book, a 2.2% yield and oversold technicals present a structured long trade for patient, ris…
Ionis (IONS) trades at a premium valuation that implies the market is pricing modest commercial success for its pipeline. Recent regulatory and clinical progress across the franchise (Dawnzera approval, positive Phase 3 readouts, multiple program wins) reduces binary risk. If peak revenue assumptions for olezarsen are conservative, the stock can re…
Ferrari trades near $321 after a corrective pullback. The underlying business still posts exceptional profitability, a heavy buyback, and a pre-sold supercar pipeline. This trade idea buys the weakness for a long-term rebound while recognizing that the brand's EV strategy is the risk that could compress multiples if execution disappoints.
Quanex Building Products (NX) combines a repaired balance sheet, strong recent free cash flow and yield support with activist interest and near-term catalysts. The stock trades at an attractive EV/sales and P/FCF multiple despite earnings volatility. We lay out a mid-term trade (45 trading days) to capture continued outperformance while protecting …
Cloudflare (NET) looks attractive here: revenue momentum and strategic partnerships are accelerating monetization of the edge platform, technicals show bullish momentum, and the company’s infrastructure could capture a material share of new stablecoin and payments routing flows. I upgrade my stance to a buy and lay out an actionable mid-term trade …
Silvaco (SVCO) is transitioning from a pure EDA vendor into a tighter set of semiconductor IP and photonics/simulation niches through targeted acquisitions. The company beat Q4 revenue and EPS expectations and has a low debt profile, but negative free cash flow and an overbought tape argue for a buy-the-dip approach. This trade idea lays out an ent…
Mastercard is pulling back from 52-week highs but remains a high-return, cash-generative network with a new $1.8B acquisition to accelerate crypto payments. Technicals show momentum exhaustion and an RSI near 36, creating a tactical entry for a mid-term swing. This idea lays out an entry, stop, targets, catalysts and risks for a measured long trade…
Ovid (OVID) just cleared two big obstacles: Phase 1 safety data for OV329 and a $60M PIPE led by Point72. With an EV well below $200M and shares trading at $2.30, the stock offers a high-risk, high-reward long trade into Phase 2 starts and program expansion news. This idea lays out a specific entry, stop, targets, catalysts and the risks that can w…
Global Payments (GPN) looks materially undervalued on multiple valuation measures and sits on roughly $2.0B of free cash flow, a $2.5B buyback authorization, and management guidance that could materially compress forward P/E if achieved. Short-term macro and geopolitical shocks tied to the Persian Gulf conflict raise execution and volatility risk, …
Legacy Housing (LEGH) trades at roughly $19.20 with a market cap near $457M, a P/E of ~11 and P/B under 1. The company generates meaningful free cash flow but faces a growth reset and execution risk. This trade idea buys the mismatch between valuation and near-term cash earnings, with a clearly defined stop and a target that assumes modest re-ratin…
Bumble’s recent cash generation plus an underappreciated tax shield create an outsized free cash flow picture even after conservative adjustments. At the current price, a disciplined long toward $6.00 over the next 45 trading days offers a risk-reward that merits a tactical allocation, provided management sustains margin recovery and execution on A…
Gold.com, Inc. (GOLD) has pulled back sharply with gold price volatility and risk-off flows. The stock now trades at an attractive free-cash-flow-backed valuation, has a modest dividend, and shows oversold technicals. This trade idea lays out an entry at $44.00, a hard stop at $38.00, and a primary target of $62.00 for the recovery trade over the n…
Marvell (MRVL) has been one of the year's strongest AI-levered performers, reporting double-digit growth and routing into custom ASICs, optics, and networking where hyperscalers are spending. The stock trades at a premium but still offers upside relative to the current share price if AI infrastructure spending continues. This trade idea lays out an…
S&P Global is uniquely positioned to monetize the AI data and benchmark arms race. Solid cash flow, recurring margins and exposure across indices, ratings and data services justify a mid-term long trade. Entry $425.00, target $520.00, stop $395.00 — horizon: mid term (45 trading days).
Boundless Bio is a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) cancers. With IND acceptance for BBI-940, $107.6M in cash runway through mid-2028, and a market cap of roughly $26M, the stock offers an asymmetric risk/reward for traders willing to stomach biotech binary events. This trade idea outlines a long trade with en…
Geely (GELYF) shows constructive technicals and a sharp decline in short interest that support a tactical long. Enter at $2.34, stop at $2.05, primary target $2.70 over the next 45 trading days.
